Pharmacokinetic evaluation of mycophenolate mofetil for pemphigus

Bibliography

• Sarma N, Ghosh S. Mycophenolate mofetil as adjuvant in pemphigus vulgaris. Indian J Dermatol Venereol Leprol 2007;73(5):348-50
   PubMed Web of Science ®Google Scholar
• Powell AM, Albert S, Al Fares S, An evaluation of the usefulness of mycophenolate mofetil in pemphigus. Br J Dermatol 2003;149(1):138-45
   PubMed Web of Science ®Google Scholar
• Harman KE, Albert S, Black MM. Guidelines for the management of pemphigus vulgaris. Br J Dermatol 2003;149(5):926-37
   PubMed Web of Science ®Google Scholar
• Esmaili N, Chams-Davatchi C, Valikhani M, Treatment of pemphigus vulgaris with mycophenolate mofetil as a steroid-sparing agent. Eur J Dermatol 2008;18(2):159-64
   PubMed Web of Science ®Google Scholar
• Benoit S, Brocker B, Schmidt S. Current treatment of pemphigus. G Ital Dermatol Venereol 2007;142:363-80
   Google Scholar
• Hertl M. Research in practice: treatment of autoimmune bullous disorders. J Dtsch Dermatol Ges 2009;7(6):500-5
   PubMed Web of Science ®Google Scholar
• Chams-Davatchi C, Esmaili N, Daneshpazhooh M, Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris. J Am Acad Dermatol 2007;57(4):622-8
   PubMed Web of Science ®Google Scholar
• Zwerner J, Fiorentino D. Mycophenolate mofetil. Dermatol Ther 2007;20(4):229-38
   PubMed Web of Science ®Google Scholar
• Langman LJ, LeGatt DF, Yatscoff RW. Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression by measuring IMP dehydrogenase activity. Clin Chem 1995;41(2):295-9
   PubMed Web of Science ®Google Scholar
• Epinette WW, Parker CM, Jones EL, Greist MC. Mycophenolic acid for psoriasis. A review of pharmacology, long-term efficacy, and safety. J Am Acad Dermatol 1987;17(6):962-71
   PubMed Web of Science ®Google Scholar
• Lipsky JJ. Mycophenolate mofetil. Lancet. 1996;348(9038):1357-9
   PubMed Web of Science ®Google Scholar
• Lee WA, Gu L, Miksztal AR, Bioavailability improvement of mycophenolic acid through amino ester derivatization. Pharm Res 1990;7(2):161-6
   PubMed Web of Science ®Google Scholar
• Allison AC. Mechanisms of action of mycophenolate mofetil. Lupus 2005;14(Suppl 1):s2-8
   PubMedGoogle Scholar
• de Winter BC, van Gelder T, Sombogaard F, Pharmacokinetic role of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipients. J Pharmacokinet Pharmacodyn 2009;36(6):541-64
   PubMed Web of Science ®Google Scholar
• Mele TS, Halloran PF. The use of mycophenolate mofetil in transplant recipients. Immunopharmacology 2000;47(2-3):215-45
   PubMedGoogle Scholar
• Carr SF, Papp E, Wu JC, Natsumeda Y. Characterization of human type I and type II IMP dehydrogenases. Biol Chem 1993;268(36):27286-90
   Web of Science ®Google Scholar
• Nowak I, Shaw LM. Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics. Clin Chem 1995;41(7):1011-17
   PubMed Web of Science ®Google Scholar
• Kitchin JE, Pomeranz MK, Pak G, Rediscovering mycophenolic acid: a review of its mechanism, side effects, and potential uses. J Am Acad Dermatol 1997;37(3 Pt 1):445-9
   PubMed Web of Science ®Google Scholar
• van Gelder T. Mycophenolate mofetil: how to further improve using an already successful drug? Am J Transplant 2005;5(2):199-200
   PubMed Web of Science ®Google Scholar
• Becker BN. Mycophenolate mofetil. Transplant Proc 1999;31(7):2777-8
   PubMed Web of Science ®Google Scholar
• Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000;47(2-3):85-118
   PubMed Web of Science ®Google Scholar
• Orvis AK, Wesson SK, Breza TS Jr, Mycophenolate mofetil in dermatology. J Am Acad Dermatol 2009;60(2):183-99
   PubMed Web of Science ®Google Scholar
• Enk AH, Knop J. Mycophenolate is effective in the treatment of pemphigus vulgaris. Arch Dermatol 1999;135(1):54-6
   PubMed Web of Science ®Google Scholar
• Jain A, Venkataramanan R, Kwong T, Pharmacokinetics of mycophenolic acid in liver transplant patients after intravenous and oral administration of mycophenolate mofetil. Liver Transpl 2007;13(6):791-6
   PubMed Web of Science ®Google Scholar
• Shaw LM, Korecka M, DeNofrio D, Brayman KL. Pharmacokinetic, pharmacodynamic, and outcome investigations as the basis for mycophenolic acid therapeutic drug monitoring in renal and heart transplant patients. Clin Biochem 2001;34(1):17-22
   PubMed Web of Science ®Google Scholar
• Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 1998;34(6):429-55
   PubMed Web of Science ®Google Scholar
• Bowalgaha K, Miners JO. The glucuronidation of mycophenolic acid by human liver, kidney and jejunum microsomes. Br J Clin Pharmacol 2001;52(5):605-9
   PubMed Web of Science ®Google Scholar
• Bullingham R, Monroe S, Nicholls A, Hale M. Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration. Clin Pharmacol 1996;36(4):315-24
   Google Scholar
• Shaw LM, Nowak I. Mycophenolic acid: measurement and relationship to pharmacologic effects. Ther Drug Monit 1995;17(6):685-9
   PubMed Web of Science ®Google Scholar
• Shipkova M, Armstrong VW, Wieland E, Identification of glucoside and carboxyl-linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. Br J Pharmacol 1999;126(5):1075-82
   PubMed Web of Science ®Google Scholar
• Gomez EC, Michaelover J, Frost P. Cutaneous beta-glucuronidase: cleavage of mycophenolic acid by preparations of mouse skin. Br J Dermatol 1977;97(3):303-6
   PubMed Web of Science ®Google Scholar
• Shaw LM, Korecka M, Venkataramanan R, Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies. Am J Transplant 2003;3(5):534-42
   PubMed Web of Science ®Google Scholar
• Cox VC, Ensom MH. Mycophenolate mofetil for solid organ transplantation: does the evidence support the need for clinical pharmacokinetic monitoring? Ther Drug Monit 2003;25(2):137-57
   PubMed Web of Science ®Google Scholar
• Weber LT, Shipkova M, Armstrong VW, The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic Acid in pediatric renal transplant recipients: a report of the german study group on mycophenolate mofetil therapy. J Am Soc Nephrol 2002;13(3):759-68
   PubMedGoogle Scholar
• Zeng L, Blair EY, Nath CE, Population pharmacokinetics of mycophenolic acid in children and young people undergoing blood or marrow and solid organ transplantation. Br J Clin Pharmacol 2010;70(4):567-79
   PubMed Web of Science ®Google Scholar
• Villarroel MC, Hidalgo M, Jimeno A. Mycophenolate mofetile :un update. Drugs today 2009;45(7):521-32
   PubMed Web of Science ®Google Scholar
• Shum B, Duffull SB, Taylor PJ, Tett SE. Population pharmacokinetic analysis of mycophenolic acid in renal transplant recipients following oral administration of mycophenolate mofetil. Br J Clin Pharmacol 2003;56(2):188-97
   PubMed Web of Science ®Google Scholar
• Ahmed AR. Drug therapy of pemphigus vulgaris. G Ital Dermatol Venereol 2007;142:391-408
   Google Scholar
• Beissert S, Minouni D, Kanwar AJ, Treating pemphigus vulgaris with prednisone and mycophenolate mofetil: a multicenter, randomized, placebo-controlled trial. J Invest Dermatol 2010;130(8):2041-8
   PubMed Web of Science ®Google Scholar
• Ong JP, Barnes DS, Younossi ZM, Outcome of de novo hepatitis C virus infection in heart transplant recipients. Hepatology 1999;30(5):1293-8
   PubMed Web of Science ®Google Scholar
• Staatz CE, Duffull SB, Kiberd B, Population pharmacokinetics of mycophenolic acid during the first week after renal transplantation. Eur J Clin Pharmacol 2005;61(7):507-16
   PubMed Web of Science ®Google Scholar
• Nousari HC, Sragovich A, Kimyai-Asadi A, Mycophenolate mofetil in autoimmune and inflammatory skin disorders. J Am Acad Dermatol 1999;40(2):265-8
   PubMed Web of Science ®Google Scholar
• Mydlarski PR. Mycophenolate mofetil: a dermatologic perspective. Skin Ther Lett 2005;10(3):1-6
   PubMedGoogle Scholar
• Ponticelli C, Passerini P. Gastrointestinal complications in renal transplant recipients. Transpl Int 2005;18(6):643-50
   PubMed Web of Science ®Google Scholar
• Davies NM, Grinyo J, Heading R, Gastrointestinal side effects of mycophenolic acid in renal transplant patients: a reappraisal. Nephrol Dial Transplant 2007;22(9):2440-8
   PubMed Web of Science ®Google Scholar
• Eaton PA, Callen JP. Mycophenolate mofetil as therapy for pyoderma gangrenosum. Arch Dermatol 2009;145(7):781-5
   PubMed Web of Science ®Google Scholar
• Hofmann SC, Kautz O, Hertl M, Results of a survey of German dermatologists on the therapeutic approaches to pemphigus and bullous pemphigoid. J Dtsch Dermatol Ges 2009;7(3):227-33
   PubMed Web of Science ®Google Scholar
• Robson R, Cecka JM, Opelz G, Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil. Am J Transplant 2005;5(12):2954-60
   PubMed Web of Science ®Google Scholar
• Beissert S, Werfel T, Frieling U, A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of pemphigus. Arch Dermatol 2006;142(11):1447-54
   PubMed Web of Science ®Google Scholar
• Bystryn JC, Steinman NM. The adjuvant therapy of pemphigus. an update. Arch Dermatol 1996;132(2):203-12
   PubMed Web of Science ®Google Scholar
• Sarma N, Ghosh S. Mycophenolate mofetil as adjuvant in pemphigus vulgaris. Indian J Dermatol Venereol Leprol 2007;73(5):348-50
   PubMed Web of Science ®Google Scholar
• Grundmann-Kollmann M, Korting HC, Behrens S, Mycophenolate mofetil: a new therapeutic option in the treatment of blistering autoimmune diseases. J Am Acad Dermatol 1999;40(6):957-60
   PubMed Web of Science ®Google Scholar
• Beissert S, Werfel T, Frieling U, A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of bullous pemphigoid. Arch Dermatol 2007;143(12):1536-42
   PubMed Web of Science ®Google Scholar
• Margolis DJ. A randomized trial and the treatment of pemphigus vulgaris. J Invest Dermatol 2010;130(8):1964-6
   PubMed Web of Science ®Google Scholar
• Mimouni D, Anhalt GJ, Cummins DL, Treatment of pemphigus vulgaris and pemphigus foliaceus with mycophenolate mofetil. Arch Dermatol 2003;139(6):739-42
   PubMed Web of Science ®Google Scholar
• Bunnapradist S, Ambuhl PM. Impact of gastrointestinal-related side effects on mycophenolate mofetil dosing and potential therapeutic strategies. Clin Transplant 2008;22(6):815-21
   PubMed Web of Science ®Google Scholar
• Bjarnason I. Enteric coating of mycophenolate sodium: a rational approach to limit topical gastrointestinal lesions and extend the therapeutic index of mycophenolate. Transplant Proc 2001;33(7-8):3238-40
   PubMed Web of Science ®Google Scholar
• Chan L, Mulgaonkar S, Walker R, Patient-reported gastrointestinal symptom burden and health-related quality of life following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium. Transplantation 2006;81(9):1290-7
   Google Scholar
• Salvadori M, Holzer H, de Mattos A, Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2004;4(2):231-6
   PubMed Web of Science ®Google Scholar
• Sabbatini M, Capone D, Gallo R, EC-MPS permits lower gastrointestinal symptom burden despite higher MPA exposure in patients with severe MMF-related gastrointestinal side-effects. Fundam Clin Pharmacol 2009;23(5):617-24
   PubMed Web of Science ®Google Scholar
• Arns W, Breuer S, Choudhury S, Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil. Clin Transplant 2005;19(2):199-206
   PubMed Web of Science ®Google Scholar
• Marzano AV, Dassoni F, Caputo R. Treatment of refractory blistering autoimmune diseases with mycophenolic acid. J Dermatolog Treat 2006;17(6):370-6
   PubMed Web of Science ®Google Scholar
• Bongiorno MR, Pistone G, Doukaki S, Arico M. Enteric-coated mycophenolate sodium in the treatment of refractory pemphigus. Int J of Dermatol 2010;49:693-9
   PubMed Web of Science ®Google Scholar
• Baskan EB, Yilmaz M, Tunali S, Saricaoglu H. Efficacy and safety of long-trrm mycophenolate sdium in pemphigus vulgaris. J Eur Acad Dermatol Venereol 2009;23(12):1432-4
   PubMed Web of Science ®Google Scholar
• Darji P, Vijayaraghavan R, Thiagarajan CM, Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant recipients with gastrointestinal tract disorders. Transplant Proc 2008;40(7):2262-7
   PubMed Web of Science ®Google Scholar